- •Many trials report “no meaningful difference” in health-related quality of life (HRQL) or function between arms despite observing notable differential toxicity. A possible explanation is that mean change from baseline analyses of function or HRQL can obscure important change in subgroups experiencing symptomatic toxicity.
- •In our case examples, for those patients who remained on treatment and completed patient-reported outcome assessments, there was a greater proportion of patients in the treatment arm reporting diarrhea. Patients reporting more frequent diarrhea reported lower physical functioning and global health status and quality of life than patients with no diarrhea, regardless of treatment arm.
- •When differential toxicity between arms is observed, additional exploratory analyses aided by data visualization that evaluate functioning or HRQL by symptomatic adverse event are needed. This information can further inform the safety and tolerability of the investigational agent under study.
- Patient-reported outcomes in OAK: a phase III study of atezolizumab versus docetaxel in advanced non-small-cell lung cancer.Clin Lung Cancer. 2018; 19: 441-449.e4
- Patient-reported quality of life outcomes in patients treated for muscle-invasive bladder cancer with radiotherapy ± chemotherapy in the BC2001 phase III randomised controlled trial.Eur Urol. 2020; 77: 260-268
- Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial.Ann Oncol. 2020; 31: 310-317
- Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.Lancet Oncol. 2018; 19: 1404-1416
- Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial.Lancet Oncol. 2019; 20: 556-569
- Subgroup analyses in confirmatory clinical trials: time to be specific about their purposes.BMC Med Res Methodol. 2016; 16: 20
- Focusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms.Clin Cancer Res. 2016; 22: 1553-1558
- US Food and Drug Administration review of statistical analysis of patient-reported outcomes in lung cancer clinical trials approved between January, 2008, and December, 2017.Lancet Oncol. 2010; 20: e582-e589
- The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.J Natl Cancer Inst. 1993; 85: 365-376
- Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. U.S. Department of Health and Human Services, National Institute of Health, National Cancer Institute.https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdfDate accessed: August 4, 2021
- Evaluating treatment tolerability in cancer clinical trials using the toxicity index.J Natl Cancer Inst. 2020; 112: 1266-1274
- Exploration of baseline patient-reported side effect bother from cancer therapy.Clin Trials. 2020; 17: 332-337